Tyra Biosciences Announces Participation at Upcoming Investor Events
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.
The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.
Webcasts of both events will be accessible through Tyra's investor relations website.
Tyra Biosciences (Nasdaq: TYRA), una biotech in fase clinica specializzata in farmaci di precisione per il recettore del fattore di crescita dei fibroblasti (FGFR), ha annunciato la propria partecipazione a due prossimi eventi per investitori.
La società prenderà parte a un fireside chat nella serie virtuale H.C. Wainwright "HCW@Home" il 21 agosto 2025 alle 11:00 ET. Inoltre, il management sarà presente al 27° Annual Global Investment Conference di H.C. Wainwright il 10 settembre 2025 alle 9:00 ET a New York, dove terrà un fireside chat e meeting individuali con investitori.
I webcast di entrambi gli eventi saranno disponibili sul sito degli investor relations di Tyra.
Tyra Biosciences (Nasdaq: TYRA), una biotecnológica en fase clínica especializada en medicamentos de precisión dirigidos al receptor del factor de crecimiento de fibroblastos (FGFR), ha anunciado su participación en dos próximos eventos para inversores.
La compañía participará en un fireside chat de la serie virtual H.C. Wainwright "HCW@Home" el 21 de agosto de 2025 a las 11:00 ET. Además, la dirección asistirá al 27.º Annual Global Investment Conference de H.C. Wainwright el 10 de septiembre de 2025 a las 9:00 ET en Nueva York, con un fireside chat y reuniones individuales con inversores.
Las transmisiones en directo de ambos eventos estarán disponibles en la web de relaciones con inversores de Tyra.
Tyra Biosciences (나스닥: TYRA)는 섬유아세포 성장 인자 수용체(FGFR) 정밀 의약품을 전문으로 하는 임상 단계의 바이오텍으로, 두 건의 투자자 행사를 발표했습니다.
회사는 2025년 8월 21일 오전 11:00(동부시간)에 열리는 가상 H.C. Wainwright "HCW@Home" 시리즈의 파이어사이드 챗에 참여합니다. 또한 경영진은 2025년 9월 10일 오전 9:00(동부시간)에 뉴욕에서 열리는 H.C. Wainwright 제27회 연례 글로벌 인베스트먼트 컨퍼런스에 참석해 파이어사이드 챗 및 일대일 투자자 미팅을 진행할 예정입니다.
두 행사 모두의 웹캐스트는 Tyra의 투자자 관계 웹사이트를 통해 시청할 수 있습니다.
Tyra Biosciences (Nasdaq : TYRA), une société biotechnologique en phase clinique spécialisée dans les médicaments de précision ciblant le récepteur du facteur de croissance des fibroblastes (FGFR), a annoncé sa participation à deux événements à venir destinés aux investisseurs.
La société participera à un fireside chat dans le cadre de la série virtuelle H.C. Wainwright "HCW@Home" le 21 août 2025 à 11h00 ET. De plus, la direction assistera à la 27e conférence annuelle mondiale d'investissement H.C. Wainwright le 10 septembre 2025 à 9h00 ET à New York, qui comprendra un fireside chat et des réunions individuelles avec des investisseurs.
Les webcasts des deux événements seront accessibles via le site relations investisseurs de Tyra.
Tyra Biosciences (Nasdaq: TYRA), ein klinisch fortgeschrittenes Biotech-Unternehmen, das sich auf präzisionsmedizinische Wirkstoffe für den Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR) spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenveranstaltungen angekündigt.
Das Unternehmen wird an einem Fireside Chat der virtuellen H.C. Wainwright "HCW@Home"-Reihe am 21. August 2025 um 11:00 Uhr ET teilnehmen. Darüber hinaus wird das Management am 27. H.C. Wainwright Annual Global Investment Conference am 10. September 2025 um 9:00 Uhr ET in New York vertreten sein, mit einem Fireside Chat und Einzelgesprächen mit Investoren.
Webcasts beider Veranstaltungen sind über die Investor-Relations-Website von Tyra abrufbar.
- None.
- None.
Virtual H.C. Wainwright "HCW@Home" series
Format: Fireside chat
Presentation Date/Time: Thursday, August 21, 2025, at 11 AM ET
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, September 10, 2025, at 9 AM ET
Location:
A live webcast of the events can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. The current planned clinical development for dabogratinib includes SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and potentially future metastatic urothelial cancer studies. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302534890.html
SOURCE Tyra Biosciences
FAQ
When is Tyra Biosciences (TYRA) presenting at the H.C. Wainwright Global Investment Conference 2025?
What type of presentations will TYRA give at the upcoming investor events?
How can investors access Tyra Biosciences' (TYRA) upcoming investor presentations?
What is Tyra Biosciences' (TYRA) main focus as a company?
